entertainment -WSS

entertainment

author：leisure time 2025-09-29 22:46:34 - browse：98

Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial.

The negative outcome of the Phase 3 study represents a setback in the company’s efforts to expand the use of Nuplazid into the treatment of schizophrenia. The medicine is currently approved to treat hallucinations and delusions associated with Parkinson’s disease psychosis.

“We are disappointed the trial did not meet its primary endpoint given the significant unmet need in patients with negative symptoms of schizophrenia,” said Acadia CEO Steve Davis, in a statement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

WSS

The response to Covid

As pharma fights Medicare drug negotiation, hospitals, docs silent

PrEP can help anyone prevent HIV. Why do so few people take it?

As pharma fights Medicare drug negotiation, hospitals, docs silent

PrEP can help anyone prevent HIV. Why do so few people take it?

Severe heat forecast: Where scorching temperatures will persist over the next week

explore

entertainment

focus

Affirmative action in medical school literally saved lives

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

After affirmative action ruling, medical educators look to 'holistic review'

Sophia Smith scores twice for US in in 3

Virginia high school admissions case could be legal follow

Winners, losers from Medicare’s list of drugs subject to price talks

Medical leaders decry Supreme Court decision on affirmative action

Radiation, mainstay of cancer treatment, begins a fade

Supreme Court strikes down use of affirmative action

2024 GOP presidential candidates spar over abortion in debate

entertainment

AstraZeneca bets AAV gene therapy will still deliver the goods

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

Winners, losers from Medicare’s list of drugs subject to price talks

PrEP can help anyone prevent HIV. Why do so few people take it?

New requirements coming in 2024 for Americans traveling to Europe

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

leisure time

focus

hotspot

leisure time